| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 546061000 | Tetracyclo ring system having the six-membered hetero ring as one of the cyclos | 41 |
| 546062000 | Plural ring hetero atoms in the tetracyclo ring system (e.g., acronycines, etc.) | 20 |
| 20140371459 | INDUSTRIAL PROCESS FOR PREPARATION OF 1,2-DIHYDROQUINOLINE DERIVATIVE OR A SALT THEREOF, AND INTERMEDIATE FOR PREPARATION THEREOF - Provided is a method for producing a compound represented by formula (7) or a salt thereof: | 12-18-2014 |
| 546063000 | Two of the cyclos share at least three ring member (i.e., bridged) | 2 |
| 20100168427 | METHOD FOR PRODUCING N-METHYLNALTREXONE BROMIDE - Process for the preparation of N-methylnaltrexone bromide, wherein a compound of the general formula (I): | 07-01-2010 |
| 20160096840 | PROCESS FOR CONVERTING LUPANINE INTO SPARTEINE - The present invention relates to processes for preparing enantiopure Lupanine and Sparteine. | 04-07-2016 |
| 546064000 | Three or more ring hetero atoms in the tetracyclo ring system | 4 |
| 20110112299 | TETRACYCLIC COMPOUND - Provided are a tetracyclic compound represented by the formula (I): | 05-12-2011 |
| 20130041153 | DERIVATIVES HAVING VINYL GROUP AND ITS USE IN ELECTROLUMINESCENT ELEMENT - The present invention relates to imidazole derivatives having vinyl group represented by general formula (I) which possess electron transporting character, have a high glass transition temperature (T | 02-14-2013 |
| 546065000 | Plural ring chalcogens in the tetracyclo ring system | 2 |
| 20090043100 | Process for Producing Optically Active Chromene Oxide Compound - [Problems] To provide an efficient process for producing an optically active chromene oxide compound which is an important intermediate for a benzopyran compound effective in the treatment of arrhythmia.
| 02-12-2009 |
| 20120316342 | THERAPEUTIC AGENT FOR HEPATITIS C - This invention provides a therapeutic agent for hepatitis C comprising, as an active ingredient, a compound having anti-HCV activity useful in treatment of hepatitis C. The therapeutic agent for hepatitis C comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. | 12-13-2012 |
| 546066000 | Ring carbon is shared by three of the cyclos | 9 |
| 20120059168 | NAPHTHALENETETRACARBOXYLIC ACID DERIVATIVES AND THEIR USE AS SEMICONDUCTORS - The present invention relates to naphthalenetetracarboxylic acid derivates, to a process for their preparation and to their use, especially as an n-type semiconductor. | 03-08-2012 |
| 20150051398 | PROCESS FOR THE PREPARATION OF TETRACARBOXYNAPHTHALENEDIIMIDE COMPOUNDS DISUBSTITUTED WITH HETEROARYL GROUPS - A process for the preparation of a tetracarboxynaphthalenediimide compound disubstituted with heteroaryl groups having general formula (I), comprising the reaction of at least one disubstituted N,N | 02-19-2015 |
| 20160130271 | REDOX ACTIVE TRIANGULAR ORGANIC MATERIALS - A redox-active triangular prism is provided. The redox-active triangular prism includes a plurality of pure enantiomers selected from a group consisting of (−)-NDI-Δ and (+)-NDI-Δ. Methods for their preparation as solvent-templated supramolecular structures and a characterization of their redox-active behavior are provided. | 05-12-2016 |
| 546067000 | The three cyclos consist of two carbocyclic rings and a five-membered hetero ring which includes a ring nitrogen (e.g., ergolines, etc.) | 6 |
| 546068000 | Chalcogen or nitrogen bonded directly to ring carbon of the six-membered hetero ring | 4 |
| 20090312553 | N-TYPE SEMICONDUCTOR MATERIALS FOR THIN FILM TRANSISTORS - A thin film transistor comprises a layer of organic semiconductor material comprising a tetracarboxylic diimide naphthalene-based compound having, attached to each of the imide nitrogen atoms, an aromatic moiety, at least one of which moieties is substituted with at least one electron donating group. Such transistors can further comprise spaced apart first and second contact means or electrodes in contact with said material. Further disclosed is a process for fabricating an organic thin-film transistor device, preferably by sublimation deposition onto a substrate, wherein the substrate temperature is no more than 100° C. | 12-17-2009 |
| 20140058108 | Lisuride, Terguride and Derivatives Thereof for Use in the Prophylaxis and/or Treatment of Fibrotic Changes - The present invention relates to the use of 5-HT | 02-27-2014 |
| 20170233387 | ISOERGOLINE COMPOUNDS AND USES THEREOF | 08-17-2017 |
| 20170233404 | ISOERGOLINE COMPOUNDS AND USES THEREOF | 08-17-2017 |
| 546069000 | Having -C(=X)-, wherein X is chalcogen, bonded directly to the six-membered hetero ring (e.g., lysergic acid, etc.) | 2 |
| 20080275240 | New and efficient process for the preperation of cabergoline and its intermediates - This invention relates to a new and efficient process for the production of dopamine agonists such as Cabergoline and the intermediates thereof. | 11-06-2008 |
| 20110137035 | PREPARATION OF MICROBIOLOGICALLY PRODUCED ERGOT ALKALOIDS - The present invention relates to a method for preparing microbiologically produced ergot alkaloids of the following formula (I), comprising the step of: a) extracting the fermentation product occurring during the biological production, said product containing at least one ergot alkaloid of formula (I), at a pH of 8-14 using an extractant with a solubility in water of 0.2 g/100 g of water to 25 g/100 g water at 20° C., wherein the amount of extractant is sufficient to form a 2-phase system together with the fermentation product. | 06-09-2011 |
| 546070000 | Two ring nitrogens in the tetracyclo ring system | 4 |
| 20100099877 | NEW 2,9-DICHLOROQUINACRIDONE IN PLATELET FORM - The present invention is directed to a new 2,9-dichloroquinacridone in platelet form, a process for its preparation and its use for coloring high molecular weight organic material. The 2,9-dichloroquinacridone in platelet form has a length of 1 to 45 μm, a width of 0.1 to 20 μm and an average thickness of 0.01 to 5 μm and is characterized in that the hue-value h in remission is ≦31 and/or the lightness L* in transmission is ≧20 and/or a decreasing b* value and an increasing a* value from an illuminating and viewing angle (aspecular angle) 45°/110° (+25°) to 45°/90° (+45°). | 04-22-2010 |
| 20110021776 | COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS - Compositions and methods for treating, preventing and/or delaying the onset and/or the development of diseases and disorders of the central nervous system are disclosed. The present disclosure relates to indoloquinoline compounds that are capable of inhibiting at least one protein kinase, and to methods for preparing and uses of such compounds. The compounds described herein are administered to patients to achieve a therapeutic effect. | 01-27-2011 |
| 20130178629 | SYNTHESIS OF 4H-BENZO[D]PYRROLO[1,2-A]THIAZOLES AND INDOLIZINO[6,7-b]INDOLE DERIVATIVES AND THEIR USE AS ANTITUMOR THERAPEUTIC AGENTS - The present invention provides a series of 2,3-bis(hydroxymethyl)-4H-benzo[d]pyrrolo-[1,2-a]thiazoles and 1,2-bis(hydroxymethyl)indolizino[6,7-b]indole derivatives and their bis(alkylcarbamates) derivatives. These derivatives were designed as bi-functional DNA cross-linking agents. The in vitro cytotoxicity study of these compounds revealed that they exhibit significant anti-proliferative activity in inhibiting human lymphoblastic leukemia and various solid tumor cell growth. The compounds also exhibit therapeutic efficacy against human breast carcinoma and lung cancer in xenograft model. The compounds generally possess potent antitumor activity to kill various human solid tumors and have high potential for clinical applications. | 07-11-2013 |
| 20160108042 | INDOLIZINO[3,2-c]QUINOLINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CYSTIC FIBROSIS CONTAINING THE SAME AS ACTIVE INGREDIENT - Provided are an indolizino[3,2-c]quinoline derivative, pharmaceutically acceptable salt thereof, and a method for preparing the same. The indolizino[3,2-c]quinoline derivative, pharmaceutically acceptable salt thereof may function as an agonist of cystic fibrosis conductance transmembrane regulator, and thus may be useful for an agent for preventing or treating diseases caused by degradation of activity of cystic fibrosis conductance transmembrane regulator and for a pharmaceutical composition for stimulating proliferation of stem cells. | 04-21-2016 |
| 546071000 | Ring nitrogen is shared by two of the cyclos | 4 |
| 20100056789 | Substituted Berbines and Processes for their Synthesis - The present invention provides processes for the synthesis of substituted berbine compounds. Also provided are intermediates used in the synthesis of substituted berbine compounds. | 03-04-2010 |
| 20100081821 | Berberine compounds and processes for the preparation of berberine compounds - The invention is directed to berberine compounds and processes for the preparation of berberine compounds through an intramolecular Bischler-Napieralski cyclization. | 04-01-2010 |
| 546072000 | Two of the cyclos share at least three ring members or a ring carbon is shared by three of the cyclos (i.e., bridged or peri-fused) | 2 |
| 20090124806 | PROCESS FOR PRODUCING CARBOXYLIC ACID FROM PRIMARY ALCOHOL - To provide an industrially-useful and environmentally-friendly novel oxidation reaction. | 05-14-2009 |
| 20150031887 | 9-AZANORADAMANTANE N-OXYL COMPOUND AND METHOD FOR PRODUCING SAME, AND ORGANIC OXIDATION CATALYST AND METHOD FOR OXIDIZING ALCOHOLS USING 9-AZANORADAMANTANE N-OXYL COMPOUND - An organocatalyst for oxidizing alcohols in which a primary alcohol is selectively oxidized in a polyol substrate having a plurality of alcohols under environmentally-friendly conditions. The organic oxidation catalyst has an oxygen atom bonded to a nitrogen atom of an azanoradamantane skeleton and at least one alkyl group at positions 1 and 5. The oxidation catalyst has higher activity than TEMPO, which is an existing oxidation catalyst, in the selective oxidation reaction of primary alcohols, and better selectivity than AZADO and 1-Me-AZADO. This DMN-AZADO can be applied to the selective oxidation reaction of primary alcohols that contributes to shortening the synthesizing process for pharmaceuticals, pharmaceutical raw materials, agricultural chemicals, cosmetics, organic materials, and other such high value-added organic compounds. | 01-29-2015 |
| 546074000 | Two of the cyclos share at least three ring members (e.g., morphinans, etc.) | 7 |
| 20090270624 | PROCESS FOR PURIFYING NOROXYMORPHONE COMPOUNDS - A process for purifying plant extracts which consist essentially of noroxymorphone compounds and which comprise, as impurities, α,β-unsaturated noroxymorphone compounds, by (a) converting the plant extract or the product of a subsequent stage in the synthesis of a selected noroxymorphone compound in a reaction which converts the hydroxyl groups present in the mixture to leaving groups of the formula —OR | 10-29-2009 |
| 20100048906 | Preparation of Substituted Morphinan-6-Ones and Salts and Intermediates Thereof - The present invention is directed to processes for the synthesis of morphinan-6-ones and salts, intermediates, and analogs thereof. | 02-25-2010 |
| 20100317861 | Remove Amination of 6-Keto Normorphinans by Catalytic Hydrogen Transfer - The present invention provides processes for the stereoselective synthesis of 6-alpha-amino morphinans. In particular, the invention provides processes for the reductive amination of 6-keto normorphinans by catalytic transfer hydrogenation. | 12-16-2010 |
| 20120316343 | Reductive Amination of 6-Keto Morphinans by Catalytic Hydrogen Transfer - The present invention provides compositions of 6-amino morphinan compounds and process for their synthesis. In particular, the processes provide for the reductive amination of 6-keto morphinans by catalytic transfer hydrogenation, to produce 6-amino morphinan compounds, which are epimerically and/or diastereomerically enriched. | 12-13-2012 |
| 20140275546 | AZAADAMANTANE FORMATE ESTER AND PROCESS FOR PREPARING AZAADAMANTANE DERIVATIVES - A compound, (4s)-1-azaadamantane-4yl formate ester, is described. In addition, a process is described for preparing (4s)-1-azaadamantane-4yl formate ester, aminothiadiazole-phenyl phosphate salt, bromothiadizole-phenyl or (4s)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.1 | 09-18-2014 |
| 20150011768 | 4-HYDROXYBENZOMORPHANS - 4-Hydroxybenzomorphans containing carboxamide or thiocarboxamide at the 3-position are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications. | 01-08-2015 |
| 20160075658 | 4-HYDROXYBENZOMORPHANS - 4-Hydroxybenzomorphans containing carboxamide or thiocarboxamide at the 3-position are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications. | 03-17-2016 |
| 546075000 | Ring carbon is shared by three of the cyclos | 7 |
| 20090247753 | Acenaphthopyridine Derivative, Material of Light-Emitting Element, Light-Emitting Element, Light-Emitting Device, and Electronic Appliance - It is an object to provide a new compound which is suitable for a material of an electron-transporting layer of a light-emitting element. In particular, it is an object to provide a compound which can be used for forming a light-emitting element capable of emitting light at a low drive voltage. An acenaphthopyridine derivative represented by the following general formula (G1) is provided. In the formula, Het represents a pyridyl group or a quinolyl group. | 10-01-2009 |
| 20100216998 | Facile "One Pot' Process for Apomorphine From Codeine - An improved method for producing apomorphine and derivatives thereof is provided. The method is a convenient ‘one-pot’ process, comprising the conversion of codeine into apomorphine without isolating the apocodeine intermediate. Use of water reactive scavengers, reagents that will react irreversibly with water, decreases side product formation and allows the use of milder reaction conditions. This one-pot synthesis of apomorphine from codeine provides a faster reaction with improved yields at temperatures lower as compared to conventional methods. The lower operating temperatures and less volatile reactants make the method particularly useful for large-scale manufacturing. | 08-26-2010 |
| 20100228032 | Process for Making Apomorphine and Apocodeine - There is provided an improved and convenient process for the synthesis of aporphines, such as apomorphine and apocodeine, by the rearrangement of the corresponding morphine or codeine derivatives. The use of a suitable water scavenger in an acid catalyzed rearrangement of the morphine derivatives unexpectedly results in a reaction temperature convenient for plant operation without sacrificing product. The method of the present invention also alleviates the cumbersome operations that were employed in the prior art to eliminate water from the reaction mixture at the elevated temperatures. This process is adaptable for the general preparation of other aporphines from the corresponding morphine congeners. | 09-09-2010 |
| 20130296571 | QUINOLINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME - The present invention relates to a novel quinoline derivative compound, an optical isomer thereof, a pharmaceutically acceptable salt thereof, and a hydrate or a solvate thereof. The novel quinoline derivative compound, the optical isomer thereof, the pharmaceutically acceptable salt thereof, and the hydrate or the solvate thereof accelerates gastrointestinal movement, and thus can effectively prevent or treat gastrointestinal motility disorders. | 11-07-2013 |
| 20140155609 | QUINOLINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME - The present invention relates to a novel quinoline derivative compound, an optical isomer thereof, a pharmaceutically acceptable salt thereof, and a hydrate or a solvate thereof. The novel quinoline derivative compound, the optical isomer thereof, the pharmaceutically acceptable salt thereof, and the hydrate or the solvate thereof accelerates gastrointestinal movement, and thus can effectively prevent or treat gastrointestinal motility disorders. | 06-05-2014 |
| 546076000 | Chalcogen bonded directly to ring carbon of the six-membered hetero ring (e.g., anthrapyridones, etc.) | 2 |
| 20100267957 | Anthraquinone Dyes As Photosensitizers In Photovoltaic Cells - The use of anthraquinone, anthrone, anthrimide or anthrapyridone as a photosensitizer dye in a metal oxide layer of a dye-sensitized photochemical solar cell. | 10-21-2010 |
| 20110028724 | POLYMERS OF NAPTHALENE TETRACARBOXYLIC DIIMIDE DIMERS - Polymers of naphthalene tetracarboxylic diimide dimmers are provided. The polymers are of the Formula I | 02-03-2011 |
| 546077000 | The six-membered hetero ring shares ring members with one other cyclo only | 3 |
| 20120029196 | PURIFICATION 4-AZA-ANDROST-1-ENE-17-OIC ACID FROM 4-AZA-ANDROSTAN-17-OIC ACID - The present invention relates to a process of separation of 4-aza-androst-1-ene-17-oic acid from 4-aza-androstan-17-oic acid, which brings to 4-aza-androst-1-ene-17-oic containing less than 0.05% w/w of 4-aza-androstan-17-oic acid, with high yield and productivity. In particular, the present invention relates to a process for the separation of 4-aza-androstan-17-oic acid from 4-aza-androst-1-ene-17-oic acid, comprising the steps of treating the crude 4-aza-androst-1-ene-17-oic acid with formic acid and recovering the purified 4-aza-androst-1-ene-17-oic acid containing 4-aza-androstan-17-oic acid in w/w % less than 0.05%. | 02-02-2012 |
| 20120157683 | PROCESS FOR THE PREPARATION OF DUTASTERIDE - The present invention provides an improved process for the preparation of Dutasteride (I) which comprises: (i) reacting 4-aza-5α-androst-1-en-3-one-17β-carboxylic acid (VII), Formula VII with sulfonic acid anhydride (RSO | 06-21-2012 |
| 20120226044 | Process for the preparation of 4-azasteroids - A process for the preparation of 4-steroids of the formula: | 09-06-2012 |
